Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-34

The most important piece of news in that Ann was that multiple patients had completed the trial.
The fact that there's been no Ann regarding negative reactions means that the trials for those patients were without complication.
We can all rightly be disappointed with the time it is taking and that the company's leadership still refuses to offer inducements to potential patients after more than a year of cash burn while we wait.
So we make progress albeit excruciatingly slow but progress it is.
This trial is only the first of many and will create a material re rate which will also be the first of many.
GLTAH.
Not advice, DYOR.